Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. DAIVOBET GEL 50MCG/G + 0.5MG/G [SIN14318P]

DAIVOBET GEL 50MCG/G + 0.5MG/G [SIN14318P]

Active ingredients: DAIVOBET GEL 50MCG/G + 0.5MG/G

Last updated 26 October 2025

Product Info

DAIVOBET GEL 50MCG/G + 0.5MG/G

[SIN14318P]

Product information

Active Ingredient and Strength

BETAMETHASONE DIPROPIONATE 0.643 MG EQV BETAMETHASONE (MICRONIZED) - 0.5 MG/G
CALCIPOTRIOL MONOHYDRATE 52.2 MCG/G EQV CALCIPOTRIOL - 0.05 MG/G

Dosage Form

GEL

Manufacturer and Country

LEO PHARMA A/S - DENMARK
LEO LABORATORIES LTD - IRELAND

Registration Number

SIN14318P

Licence Holder

DKSH SINGAPORE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

D05AX52

Indications
Topical treatment of scalp psoriasis. Topical treatment of “non-scalp” plaque psoriasis vulgaris.

Posology and method of administration
Posology
Daivobet® Gel should be applied to affected areas once daily. The recommended treatment period is 4 weeks for scalp areas and 8 weeks for “non-scalp” areas. If it is necessary to continue or restart treatment after this period, treatment should be continued after medical review and under regular medical supervision.

When using calcipotriol containing medicinal products, the maximum daily dose should not exceed 15 g, and the maximum weekly dose should not exceed 100 g. The body surface area treated with calcipotriol containing medicinal products should not exceed 30%.

If used on the scalp
All the affected scalp areas may be treated with Daivobet® Gel. Usually an amount between 1 g and 4 g per day is sufficient for treatment of the scalp (4 g corresponds to one teaspoon).

Special Populations
Renal and hepatic impairment
The safety and efficacy of Daivobet® Gel in patients with severe renal insufficiency or severe hepatic disorders have not been evaluated.

Paediatric population
The safety and efficacy of Daivobet® Gel in children below 18 years have not been established.
Currently available data in children aged 12 to 17 years are described in sections Undesirable effects and Pharmacodynamics properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information, but no recommendation on a posology can be made.

Method of administration
Daivobet® Gel should not be applied directly to the face or eyes. In order to achieve optimal effect, it is not recommended to take a shower or bath, or to wash the hair in case of scalp application, immediately after application of Daivobet® Gel. Daivobet® Gel should remain on the skin during the night or during the day.

When using the bottle
The bottle should be shaken before use and Daivobet® Gel applied to the affected area. The hands should be washed after use.

Contraindications
Hypersensitivity to the active substances or to any of the excipients.

Due to the content of calcipotriol, Daivobet® Gel is contraindicated in patients with known disorders of calcium metabolism.

Due to the content of corticosteroid, Daivobet® Gel is contraindicated in the following conditions: Viral (e.g. herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis, perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers, wounds and perianal and genital pruritus.

Daivobet® Gel is contraindicated in erythrodermic, exfoliative and pustular psoriasis.